Vetr Top Raters Upgrade Juno Therapeutics To 4.5-Star Stock

Shares of Juno Therapeutics Inc JUNO have lost nearly 25 percent of its value since the start of 2016 which likely prompted Vetr top raters to recognize value in its stock at a deflated price. Vetr top raters upgraded Juno Therapeutics' stock rating to 4.5-stars out of a possible 5-stars. In fact, shares of Juno Therapeutics have risen to $33.71 since the prior rating of 3.5-stars was issued just 6 days ago. Related link: Here's how crowdsourced ratings can beat the market.

In addition to being upgraded to bull territory, 100 percent of the crowd's ratings are bullish and the crowd sourced price target of $37.81 implies a potential upside of more than 12 percent.